EDIT vs OGN · rev $32.3M vs P/E 3.4, rev $6.40B
Editas Medicine Inc (EDIT) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
EDIT currently screens at market cap $375.2M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the EDIT and OGN stock pages for the full models.
Not investment advice.